[8-K] BioXcel Therapeutics, Inc. Reports Material Event
BioXcel Therapeutics furnished a press release announcing financial results for the three months ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Form 8-K. The company expressly states the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and therefore is not incorporated by reference into registration statements except as expressly noted.
The report also identifies Exhibit 104 (cover page interactive XBRL tags). The Form itself does not contain the financial line items or tables; readers must consult Exhibit 99.1 for the detailed results and the business commentary.
BioXcel Therapeutics ha diffuso un comunicato stampa con i risultati finanziari relativi ai tre mesi chiusi al 30 giugno 2025 e ha fornito un aggiornamento sulla situazione aziendale; tale comunicato 猫 allegato come Exhibit 99.1 al presente Form 8-K. La societ脿 precisa espressamente che l'informazione 猫 furnished e non deve essere considerata "filed" ai fini della Sezione 18 dello Exchange Act, e pertanto non 猫 incorporata per riferimento nelle dichiarazioni di registrazione salvo ove espressamente indicato.
Il rapporto indica inoltre il Exhibit 104 (tag XBRL interattivi della copertina). Il Form stesso non contiene le voci o le tabelle finanziarie; i lettori devono consultare l'Exhibit 99.1 per i risultati dettagliati e i commenti sull'attivit脿.
BioXcel Therapeutics public贸 un comunicado de prensa con los resultados financieros correspondientes a los tres meses terminados el 30 de junio de 2025 y ofreci贸 una actualizaci贸n de negocios; dicho comunicado se incluye como Exhibit 99.1 en este Form 8-K. La compa帽铆a declara expresamente que la informaci贸n se est谩 furnished y no debe considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act, por lo que no se incorpora por referencia en los formularios de registro salvo que se indique expresamente lo contrario.
El informe tambi茅n identifica el Exhibit 104 (etiquetas XBRL interactivas de la portada). El Form en s铆 no contiene las partidas o tablas financieras; los lectores deben consultar el Exhibit 99.1 para los resultados detallados y los comentarios sobre la actividad empresarial.
BioXcel Therapeutics電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴(3臧滌洈)鞚� 鞛瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頃橁碃 靷梾 順勴櫓 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� 氤� Form 8-K鞚� Exhibit 99.1鞙茧 觳秬霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 頃措嫻 鞝曤炒臧� furnished霅� 瓴冹澊氅�, Exchange Act鞚� Section 18 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 雼Μ 氇呾嫓霅橃 鞎婋姅 頃� 霌彪氇呾劯靹滌棎 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�.
氤搓碃靹滊姅 霕愴暅 響滌鞚� 雽�頇旐槙 XBRL 韮滉犯鞚� Exhibit 104鞚� 氇呾嫓頃╇媹雼�. 氤� Form 鞛愳泊鞐愲姅 鞛 頃鞚措倶 響滉皜 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 鞛愳劯頃� 瓴瓣臣鞕� 靷梾 甏�霠� 靹る獏鞚� Exhibit 99.1鞚� 彀戈碃頃挫暭 頃╇媹雼�.
BioXcel Therapeutics a diffus茅 un communiqu茅 de presse annon莽ant les r茅sultats financiers pour les trois mois clos le 30 juin 2025 et a fourni une mise 脿 jour commerciale ; ce communiqu茅 est inclus en tant que Exhibit 99.1 dans ce Form 8-K. La soci茅t茅 indique express茅ment que l'information est furnished et ne doit pas 锚tre r茅put茅e 芦 filed 禄 aux fins de la Section 18 de l'Exchange Act, et n'est donc pas incorpor茅e par renvoi dans les d茅clarations d'enregistrement sauf indication expresse contraire.
Le rapport identifie 茅galement le Exhibit 104 (balises XBRL interactives de la page de couverture). Le Form lui-m锚me ne contient pas les postes ou tableaux financiers ; les lecteurs doivent consulter l'Exhibit 99.1 pour les r茅sultats d茅taill茅s et les commentaires sur l'activit茅.
BioXcel Therapeutics ver枚ffentlichte eine Pressemitteilung mit den Finanzergebnissen f眉r die drei Monate zum 30. Juni 2025 und gab ein Gesch盲ftsupdate; diese Pressemitteilung ist als Exhibit 99.1 diesem Form 8-K beigef眉gt. Das Unternehmen stellt ausdr眉cklich fest, dass die Informationen furnished werden und nicht als "filed" im Sinne von Section 18 des Exchange Act gelten sollen und daher, soweit nicht ausdr眉cklich angegeben, nicht durch Verweis in Registrierungsdokumente aufgenommen werden.
Der Bericht weist zudem auf das Exhibit 104 (interaktive XBRL-Tags der Titelseite) hin. Das Formular selbst enth盲lt keine Finanzposten oder -tabellen; detaillierte Ergebnisse und gesch盲ftliche Erl盲uterungen sind dem Exhibit 99.1 zu entnehmen.
- Press release furnished announcing financial results for the three months ended June 30, 2025 and a business update (Exhibit 99.1)
- Cover page XBRL tags included via Exhibit 104, improving machine-readable disclosure of the cover page
- Form does not include the financial figures or tables; investors must consult Exhibit 99.1 for detailed results
- Disclosure is "furnished" not "filed", so the press release is not automatically incorporated by reference into other registration statements
Insights
TL;DR: Routine earnings disclosure furnished via press release; the Form signals disclosure but contains no in-line financial details鈥攊mpact is neutral.
The Form 8-K indicates BioXcel distributed a press release with quarterly results and a business update and furnished it as Exhibit 99.1. Because the release is furnished rather than filed, the company has met disclosure obligations while limiting automatic incorporation into other SEC filings. The filing includes XBRL cover page tags (Exhibit 104), which aids machine readability. Investors must review Exhibit 99.1 for actual revenue, expense, and cash metrics; the Form alone provides no numeric data.
TL;DR: Compliance disclosure completed by furnishing an earnings press release; procedural but not materially informative without the exhibit.
From a governance and disclosure standpoint, the company followed standard practice by furnishing its earnings release and noting the limited legal effect of furnished materials. The inclusion of Exhibit 104 suggests attention to structured reporting. However, the substantive information investors need is contained in Exhibit 99.1 rather than the body of the Form, so this filing functions primarily as a pointer to the press release rather than a standalone disclosure of financial performance.
BioXcel Therapeutics ha diffuso un comunicato stampa con i risultati finanziari relativi ai tre mesi chiusi al 30 giugno 2025 e ha fornito un aggiornamento sulla situazione aziendale; tale comunicato 猫 allegato come Exhibit 99.1 al presente Form 8-K. La societ脿 precisa espressamente che l'informazione 猫 furnished e non deve essere considerata "filed" ai fini della Sezione 18 dello Exchange Act, e pertanto non 猫 incorporata per riferimento nelle dichiarazioni di registrazione salvo ove espressamente indicato.
Il rapporto indica inoltre il Exhibit 104 (tag XBRL interattivi della copertina). Il Form stesso non contiene le voci o le tabelle finanziarie; i lettori devono consultare l'Exhibit 99.1 per i risultati dettagliati e i commenti sull'attivit脿.
BioXcel Therapeutics public贸 un comunicado de prensa con los resultados financieros correspondientes a los tres meses terminados el 30 de junio de 2025 y ofreci贸 una actualizaci贸n de negocios; dicho comunicado se incluye como Exhibit 99.1 en este Form 8-K. La compa帽铆a declara expresamente que la informaci贸n se est谩 furnished y no debe considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act, por lo que no se incorpora por referencia en los formularios de registro salvo que se indique expresamente lo contrario.
El informe tambi茅n identifica el Exhibit 104 (etiquetas XBRL interactivas de la portada). El Form en s铆 no contiene las partidas o tablas financieras; los lectores deben consultar el Exhibit 99.1 para los resultados detallados y los comentarios sobre la actividad empresarial.
BioXcel Therapeutics電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴(3臧滌洈)鞚� 鞛瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頃橁碃 靷梾 順勴櫓 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� 氤� Form 8-K鞚� Exhibit 99.1鞙茧 觳秬霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 頃措嫻 鞝曤炒臧� furnished霅� 瓴冹澊氅�, Exchange Act鞚� Section 18 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 雼Μ 氇呾嫓霅橃 鞎婋姅 頃� 霌彪氇呾劯靹滌棎 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�.
氤搓碃靹滊姅 霕愴暅 響滌鞚� 雽�頇旐槙 XBRL 韮滉犯鞚� Exhibit 104鞚� 氇呾嫓頃╇媹雼�. 氤� Form 鞛愳泊鞐愲姅 鞛 頃鞚措倶 響滉皜 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 鞛愳劯頃� 瓴瓣臣鞕� 靷梾 甏�霠� 靹る獏鞚� Exhibit 99.1鞚� 彀戈碃頃挫暭 頃╇媹雼�.
BioXcel Therapeutics a diffus茅 un communiqu茅 de presse annon莽ant les r茅sultats financiers pour les trois mois clos le 30 juin 2025 et a fourni une mise 脿 jour commerciale ; ce communiqu茅 est inclus en tant que Exhibit 99.1 dans ce Form 8-K. La soci茅t茅 indique express茅ment que l'information est furnished et ne doit pas 锚tre r茅put茅e 芦 filed 禄 aux fins de la Section 18 de l'Exchange Act, et n'est donc pas incorpor茅e par renvoi dans les d茅clarations d'enregistrement sauf indication expresse contraire.
Le rapport identifie 茅galement le Exhibit 104 (balises XBRL interactives de la page de couverture). Le Form lui-m锚me ne contient pas les postes ou tableaux financiers ; les lecteurs doivent consulter l'Exhibit 99.1 pour les r茅sultats d茅taill茅s et les commentaires sur l'activit茅.
BioXcel Therapeutics ver枚ffentlichte eine Pressemitteilung mit den Finanzergebnissen f眉r die drei Monate zum 30. Juni 2025 und gab ein Gesch盲ftsupdate; diese Pressemitteilung ist als Exhibit 99.1 diesem Form 8-K beigef眉gt. Das Unternehmen stellt ausdr眉cklich fest, dass die Informationen furnished werden und nicht als "filed" im Sinne von Section 18 des Exchange Act gelten sollen und daher, soweit nicht ausdr眉cklich angegeben, nicht durch Verweis in Registrierungsdokumente aufgenommen werden.
Der Bericht weist zudem auf das Exhibit 104 (interaktive XBRL-Tags der Titelseite) hin. Das Formular selbst enth盲lt keine Finanzposten oder -tabellen; detaillierte Ergebnisse und gesch盲ftliche Erl盲uterungen sind dem Exhibit 99.1 zu entnehmen.
FAQ
What did BioXcel (BTAI) disclose in this Form 8-K?
Where can I find the actual financial results for BTAI's quarter?
Is the information in the press release considered "filed" with the SEC?
What exhibits are included with this Form 8-K?
Does the Form 8-K include financial tables or XBRL data for the results?
